NIVEGU.KNOW BEFORE YOU FLY

THE WORLD OF AVIATION.
YOUR JOURNEY, EXPLAINED.

Search Plan my trip
NASDAQ / LIVE COMPANY INTELLIGENCE

Alterity Therapeutics Limited

Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.

TICKERATHE
CORENasdaq-listed company
WATCHEarnings + filings + operating news
STATUSContinuously updated
LIVE / ATHE COVERAGE

What’s moving Alterity Therapeutics Limited now

Current reporting with the operating signal separated from the noise.

01
Q4 FY26 Quarterly Cash Flow Report & Corporate Update

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Releases Appendix 4C

The story matters when it changes Alterity Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
02
ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

The story matters when it changes Alterity Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
03
Depositary Receipt (ATHE) price target increased by 66.70% to 6.64

Alterity Therapeutics Limited

The story matters when it changes Alterity Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
04
Depositary Receipt (ATHE) with Speculative Buy Recommendation

Canaccord Genuity Initiates Coverage of Alterity Therapeutics Limited

The story matters when it changes Alterity Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
05
Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability

Alterity Therapeutics Limited's (ASX:ATH) Path To Profitability

Investors are testing whether Alterity Therapeutics Limited’s operating performance supports its strategy and valuation.

Watch next: the filing, cash flow, guidance and capital-expenditure plan.
06
Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy

Alterity Therapeutics Limited (ATHE) Announces Positive Topline Data From Phase 2 Trial of ATH434 in Multiple System Atrophy

The story matters when it changes Alterity Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
07
Depositary Receipt () (ATHE) with Buy Recommendation

Maxim Group Initiates Coverage of Alterity Therapeutics Limited

The story matters when it changes Alterity Therapeutics Limited’s customers, execution, competitive position or capital requirements.

Watch next: confirmation in a company filing, official release or regulator record.
PRIMARY DOCUMENTS / SEC EDGAR

Latest ATHE filings.

Investor-relevant reports are shown first, followed by the company’s other recent official submissions.

6-KOfficial SEC filingFiled 2026-09-25 · Period 2026-09-30SEC ↗6-KOfficial SEC filingFiled 2026-09-23 · Period 2026-09-30SEC ↗S-8Official SEC filingFiled 2026-09-18SEC ↗6-KOfficial SEC filingFiled 2026-09-18 · Period 2026-09-30SEC ↗6-KOfficial SEC filingFiled 2026-09-16 · Period 2026-09-30SEC ↗4Official SEC filingFiled 2026-09-08 · Period 2026-08-31SEC ↗4Official SEC filingFiled 2026-09-08 · Period 2026-08-31SEC ↗6-KOfficial SEC filingFiled 2026-09-08 · Period 2026-09-30SEC ↗
EARNINGS / QUARTERLY TRACKER

Alterity Therapeutics Limited, quarter by quarter.

Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.